prophylactically in women liable to recurrent urinary infections. Results of four previous comparative clinical trials 12, 14, 16, 18 involving 173 patients have been combined, added to data from 46 other patients given long-term nitrofurantoin but not in a trial, and reanalysed. Thus, sub-groups of interest (e.g. the elderly, those allergic to antibiotics, those with congenital or acquired radiological abnormalities) have been enlarged.
As the trials were carried out in a homogeneous but shifting patient group, in a single centre under the same circumstances and using virtually identical protocols, this is not a meta-analysis of the usual kind.
Patients and methods
The types of patient, the workings of the Urinary Infection Clinic and the way in which prophylaxis was administered have been described previously. [12] [13] [14] [15] [16] 18, [23] [24] [25] All patient data were recorded on special Clinical Record Forms (CRFs). Forty-three patients took one 50 mg tablet of the microcrystalline formulation every 12 h, 110 took one 100 mg capsule of Macrodantin at bedtime, and 66 took one 50 mg capsule of Macrodantin at bedtime. Patients were advised to take the medication with a snack or with milk. The recommended course was 12 months. Prophylaxis was not started until a midstream specimen of urine (MSU) had been shown to be sterile.
Microbiological methods
These were as described previously. 24 A urinary infection was defined as an MSU growing 10 /mL. Rectal swabs or faeces were plated on MacConkey agar, and discs (200 g) of nitrofurantoin were placed on the pool and spread areas. After overnight incubation any colonies growing within the zone of inhibition around the discs were subcultured, identified and their resistance to nitrofurantoin confirmed on IsoSensitest agar.
Analysis of data
As the efficacy of long-term prophylaxis cannot be assessed by a simple 'cure/fail' analysis, we used different methods. Cumulation of data. The total length of time for which prophylaxis was taken by all assessable patients was divided by the total number of symptomatic attacks during that time, giving the mean number of episodes during prophylaxis. This was compared with the figure obtained, using the same process, for the year before the start of prophylaxis.
Results in individual patients. The numbers of patients experiencing no symptomatic attacks, and of those having no bacteriuric episodes, during prophylaxis were calculated.
The progress of each patient during and after the period of prophylaxis was compared with their immediate prehistory. Each patient was scored-separately for the two periods-as 'improved', 'no improvement' or 'not calculable', in terms of whether the frequency of symptomatic episodes had decreased during, and after, prophylaxis.
Results

Patient entry
CRFs from all 219 patients were assessed for adverse events. Forty-six patients were not assessable for clinical efficacy, as they had completed 3 months' prophylaxis, usually as a result of withdrawal by reason of an adverse event (67%) or non-compliance.
Patient characteristics
Age. The overall pattern (Figure 1 ) was the same for all the patients entered (219) as for those who were assessable for clinical efficacy (173). The age range was 9-89 years (median 31-35 years, mode 26-30 years). Most patients were 40 years of age (61%), 26% were in the middle age groups (41-65 years) and 14% were aged 65 years. Incidence of recurrence. The incidence of symptomatic episodes during the 12 months immediately before entry is shown in Figure 2 . The range was 1-12, with a median of 6 and a mode of 4. The one patient who had only one infection had recently undergone a renal transplant and was given prophylaxis in view of the potentially serious consequences of another infection. Taking an arbitrary value of 15 for any figures of 12, there was a total of 1191 episodes, giving a mean of 6.9 attacks/year/patient before prophylaxis. Nature of most recent infecting organism. In 139 of the patients (80.3%) the organism causing their most recent infection had been identified, usually by our laboratory. Eighty-two percent of these infections had been caused by Escherichia coli, 6.5% by Klebsiella pneumoniae and the remainder by nine other bacterial species. Allergies to antibiotics. Twenty-five patients (14.4%) were allergic to an antimicrobial agent, most commonly alactam (6.4%) or an anti-folate (6%). Radiological findings. More than 90% of the patients (157) had been investigated by means of an intravenous pyelogram, and many by another form of imaging in addition. At least one abnormality was found in 37 (23.6%); see Table I .
Results of prophylaxis
Adverse events. Eighty-one patients (40%) reported some form of adverse event. The incidence, especially for nausea, differed between the three dosage groups (Table  II) . Nausea was most common with the microcrystalline form; halving the dose of Macrodantin did not further reduce the incidence. For 'all adverse events', there was a clear trend indicating the lowest incidence with 50 mg Macrodantin od, intermediate with 100 mg Macrodantin od and highest with 50 mg microcrystalline bd. The only statistically significant difference was between 50 mg Macrodantin od and 50 mg microcrystalline nitrofurantoin bd. Adverse events relating to the gastro-intestinal tract were most common, with the genito-urinary tract second, skin third and then 'others' (Table III) .
No adverse event was of the 'serious' type reported for nitrofurantoin, 26 i.e. pneumonitis, liver damage, etc. No eosinophilia was found. One patient reported a peripheral neuritis (tingling of the finger tips) after 12 months' prophylaxis with 100 mg od (c.37 g), but this disappeared soon after stopping treatment.
Any changes in biochemical or haematological parameters could be explained fully by concomitant conditions.
Older patients were not more likely to experience an adverse event than younger ones. The incidence of 'all adverse events' in patients 65 years was 29% (9/31), as compared with 38.2% (72/188) in those 65 years (difference not significant).
Almost all (89%) of those who stopped treatment because of nausea did so within the first month. For those who persisted, and in the minority (c.25%) of patients who reported nausea later, nausea virtually disappeared after the third month. Thus, patients who experience nausea should be encouraged to carry on taking the medication. Only five patients reported vomiting. Length of time taking prophylaxis. The following data refer to the 173 clinically assessable patients only.
The mean period of prophylaxis was 9.9 months (range 3-12 months, median and mode 12 months), 106 patients (61.3%) completing the full 12 month course (Figure 3) . The reasons for patients not completing the prescribed course are largely unknown; several patients moved away, and a few became pregnant and decided or were advised (not by the clinic staff) to stop taking the medication.
However, in most cases patients failed to keep a scheduled appointment and did not attend the clinic again, despite three follow-up letters.
Outcome of prophylaxis. (i) Symptomatic episodes.
Half the patients (50.3%) had no symptomatic episodes while taking prophylaxis (Figure 4 ; range 0-8, median and mode 0). In all, 184 episodes were recorded, giving a mean of 1.06 episodes/patient/period of prophylaxis. As the latter parameter was 9.9 months (see above), the mean per year is 1.28 episodes/patient, compared with a pre-prophylaxis figure of 6.9 (see above). Thus, prophylaxis caused a reduction in the mean incidence of symptomatic episodes of 5.4-fold. In a small number of patients prophylaxis failed, accounting for a disproportionately large number of episodes; for example, nine patients (5.2%) experienced a total of 52 episodes (28.3%).
(ii) Bacteriuric episodes. One hundred and forty-six patients (84.4%) remained infection-free while taking prophylaxis. There were 43 infections: 16 patients had one infection, eight had two, two had three and one had five. The pattern of organisms causing breakthrough infections (Table IV ) differed from that causing the infection preceding prophylaxis, in that, as expected, E. coli was less common as a breakthrough pathogen (59% vs 82%; P 0.01). Only nine of the strains causing breakthrough infections (21%) were resistant to nitrofurantoin. (iii) Individual patient outcome. Patients were scored as 'improved' or 'not improved', as described in 'Patients and clinical methods'. Three patients (e.g. those with few attacks in the previous year, and who did not complete a full 12 month course) could not be assessed in this way. There were no clear differences between treatment groups, so results were pooled. One hundred and fortythree patients (84%) were scored as having 'improved'. There was no difference in outcomes between those with and those without a radiological abnormality.
(iv) Effect of nitrofurantoin on faecal flora. Data from 92 patients were available. Before prophylaxis, resistant organisms were found in only four patients (two Pseudomonas aeruginosa, and one each of Pseudomonas fluorescens and Proteus mirabilis). These species were not found in later samples from the same patients. During prophylaxis, no resistant organisms were found in 80 patients; the following species were isolated from the remaining 12: four Proteus spp., two each of P. aeruginosa and Acinetobacter spp., one each of Alcaligenes sp., Achromobacter sp., Morganella morganii and E. coli. None of these caused a breakthrough infection. Nitrofurantoin-sensitive coliforms were present in almost all patients.
Thus, nitrofurantoin, unlike trimethoprim, does not select for resistant bowel flora and, unlike norfloxacin, it does not remove coliforms from the flora. Outcome after prophylaxis has ended. Eighty-eight patients (55%) attended follow-up 3 and 6 months after prophylaxis had ended. Almost half (42.6%) of these maintained the improvement shown during prophylaxis. However, the remaining 45% of patients did not take advantage of the daily 'walk-in' facility, suggesting strongly that most of these did not have symptomatic episodes during the follow-up period.
Discussion
Inappropriate use of prophylactic antibiotics is unhelpful to patients and encourages emergence of resistance. 27 However, prophylaxis with a carefully chosen drug can be justified for recurrent urinary infections, since it is directed at a highly susceptible group of patients. For prophylactic use, the effective daily dosage is about one-quarter of that used therapeutically.
Understanding the pathogenesis of urinary infection allows alternative and complementary strategies for prophylaxis to be used. Thus, potential pathogens may be removed from the bowel flora, peri-urethral colonization discouraged, and a barrier of antibacterial urine maintained (Table V) .
Methenamine salts generate formaldehyde in an acid urine, and so inhibit bacterial growth. However, clinical results have been less than optimal, and some patients find the large tablets difficult to swallow. Topical antiseptics (e.g. povidone iodine wash or cream) applied to the perineal area have proved disappointing. It is difficult to remove colonizing bacteria in this way, 28 and the importance of the peri-urethral flora has been overemphasized, 29 making this an unsuitable target. Trimethoprim, alone or in co-trimoxazole, acts in three ways, and initially gave excellent results. 13, 14 However, as plasmidmediated resistance became more common, from 1980 onwards patients given these agents rapidly became colonized with resistant coliforms, and the prophylactic efficacy of these agents decreased rapidly. Fluoroquinolones behave in a similar way to trimethoprim. Their long half-lives and high intrinsic activities mean that one dose daily will ensure a permanently antibacterial urine for as long as the drug is given. These agents should remain effective until resistance emerges in E. coli, but they are unsuitable for women trying to become pregnant. 30 First-generation oral cephalosporins do not affect the faecal or peri-urethral flora, and a single low dose (e.g. 250 mg) will render the urine antibacterial for only part of the day. These compounds have a short halflife (c.1 h), but giving them at bedtime considerably lengthens their period of residence in the urine, due to the nocturnal production of anti-diuretic hormone and the lack of fluid intake during sleep. This accounts for the good results that have been obtained. 6, 9, 18, 31 Nitrofurantoin resembles the cephalosporins in the way it acts prophylactically. We show above that it remains effective even in a small dose (50 mg) taken at bedtime. Neither acquired nor intrinsic resistance developed during therapy.
The type of patient seen in our clinic remained homogeneous over the years; a large and steady turnover ensured that our studies did not involve the same patients being enrolled time and time again. Patients discharged from the clinic when their condition improved could return without formality if necessary. In the event, few a -, no effect; , an effect that would be expected to be advantageous to a prophylactic action, i.e. coliforms eliminated or reduced in number, or an antibacterial urine established.
  
patients actually returned, suggesting that a successful course of prophylaxis had cured their problem of recurrent infection.
The procedure for managing a patient on nitrofurantoin prophylaxis involves: (i) explaining what is to happen and why, in order to obtain the patient's cooperation; (ii) starting prophylaxis as soon as an MSU is shown to be free of infection; (iii) withholding prophylaxis during treatment for any breakthrough infections, and starting again immediately the acute treatment has stopped; (iv) dispensing antibiotic at intervals rather than giving a year's supply at once, as a check on compliance; (v) encouraging patients experiencing nausea during the initial phases to perservere, as this adverse event usually disappears after a few weeks. The macrocrystalline formulation caused less nausea than did the microcrystalline preparation.
This management plan can be initiated and supervised by a family doctor. Patients with a radiological abnormality benefited as much from prophylaxis as did those with no such findings, showing that this investigation is unnecessary in patients for whom long-term prophylaxis is contemplated. However, failure of prophylaxis to control recurrence may be an indication for radiological and other investigations.
Our results show that prophylaxis should continue for 12 months, as this gives a better result than a shorter period. 8, 10, 11, 32 Most patients had a reduced recurrence rate while taking prophylactic nitrofurantoin for 1 year, and often maintained this improvement after prophylaxis was stopped.
About 15% of patients did not respond to nitrofurantoin or to other prophylactic antibiotics. The reasons for this are unknown, and such patients did not show any particular characteristics that enabled them to be recognized. Breakthrough infection with resistant bacteria was not a problem. Possibly some members of this sub-group suffer from attacks of symptoms in the absence of bacteriuria (the 'urethral syndrome' 33 ), in which case antibiotic treatment could not be expected to be effective.
Nitrofurantoin has been used for almost 40 years, and it is remarkable that there has been hardly any increase in resistance during that time (Table VI; see also Grüneberg   3 4 and Winstanley et al. 35 ), in contrast to other antibiotics. Long-term use of nitrofurantoin did not select for resistant organisms in the intestinal flora, and intrinsically resistant species such as Proteus spp. and Pseudomonas spp. caused only four of the 43 (9%) breakthrough infections recorded. The incidence of Proteus spp. as urinary tract pathogens has declined significantly over the past 20 years, a finding also made by Grüneberg. 34 The reasons for this decline are not known.
The continuous use of a drug for a period of 12 months represents a very stern test, especially in terms of patient compliance. We did not attempt any formal check on compliance by 'pill counting' (which is notoriously unreliable 36 ), but found that our policy of issuing medication in the clinic at planned intervals allowed us a certain degree of control. Some patients readily admitted to occasional 'drug holidays', but because many patients commented favourably on the regimen we felt that compliance was good in most patients. It can only be speculated as to how often breakthrough infections by nitrofurantoin-sensitive bacteria (Table IV) were due to non-compliance.
In conclusion, our experience over 18 years, involving 142 patient-years of treatment, shows nitrofurantoin to be an inexpensive, effective and acceptable means by which to control recurrent urinary infections. We recommend a dose of 50 mg Macrodantin at night for a period of 12 months; the drug cost 30 of a year's prophylaxis (£37.11) compares favourably with the cost of treating the predicted numbers of acute episodes had prophylaxis not been given. Lilly Industries, who also supplied the nitrofurantoin used as comparator. The data analysis in the present study was sponsored in part by Procter & Gamble Pharmaceuticals UK Ltd.
